Arch Virol (2007) 152: 1045 DOI 10.1007/s00705-007-0968-3 Printed in the Netherlands Koff WC, Kahn P, Gust I: Aids Vaccine Development. Challenges and Opportunities. 151 pp, Caister Academic Press, 2007. ISBN 978 – 1 – 904455-11-0, $99, £49, EUR 89. It has been estimated that 40 million people were living with chapters that discuss the antigenic diversity of the virus, the HIV=AIDS in 2005 and that 25 million have already died choice of vaccine immunogens, the properties of neutralizing since the epidemic began. Every day, there are 14,000 new monoclonal antibodies, and cell-mediated and mucosal im- HIV infections and 8000 deaths due to AIDS. In some Sub- munity. Part 4 contains ﬁve chapters that describe the main Saharan African countries, the HIV prevalence rate is greater candidate vaccines that have been tested in clinical trials than 30% and life expectancy has decreased by nearly 50%. since 1987, emphasizing ongoing Phase I and II trials. The There is no doubt that the HIV=AIDS pandemic is one of ﬁrst two Phase III HIV vaccine efﬁcacy trials completed in the worst public health issues that humanity is facing today. 2003 showed that the two candidate vaccines that were tested Since the discovery of HIV more than 25 years ago, an did not signiﬁcantly protect against HIV infection and had no enormous amount of research has been devoted to the virus, impact on viral load in subjects who became HIV-infected making it by far the virus we know most about. It is all the post-vaccination. Data from two ongoing efﬁcacy trials will more extraordinary, therefore, that the most successful inter- not be available until 2009 and it is only in the decade 2010– vention which has halted the spread of viral epidemics in the 2020 that it will become clear if any of the current candidate past, namely the development of a vaccine, has completely vaccines will provide a signiﬁcant public health beneﬁt. failed in the case of HIV. Several chapters discuss the difﬁculties of conducting efﬁ- This timely book reviews in considerable detail the nu- cacy trials in developing countries and emphasize how essen- merous scientiﬁc challenges and problems that have made tial it is to do this type of work in the resource-poor regions the search for an effective AIDS vaccine so far unsuccessful. that are hardest hit by the epidemic. Part 5 devotes four The editors have secured the help of over 40 internationally chapters to important issues that often receive insufﬁcient known experts in AIDS vaccine research and have assembled attention in discussions of vaccine science, namely vaccine a 19-chapter volume that is essential reading for all those in- scale-up and manufacturing, stringent regulatory issues and terested in current attempts at developing an AIDS vaccine. the need to speed up the transfer of new vaccines from de- The book is divided in ﬁve parts. The ﬁrst part consists of veloped to developing nations two chapters that give a global overview of the epidemic and The book contains about 500 scientiﬁc references and a summarize the challenges associated with AIDS vaccine wealth of up to date information. It is highly recommended development. The second part consists of three chapters that for everyone interested in what is no doubt one of the most describe the biology of early HIV infection and our current challenging public health issues of the 21st century. understanding of protective immunity to HIV, including what we have learned from animal models. The third part is M. H. V. van Regenmortel devoted to preclinical vaccine development and contains ﬁve CNRS, Strasbourg, France Verleger: Springer-Verlag GmbH, Sachsenplatz 4–6, 1201 Wien, Austria – Herausgeber: Dr. M. H. V. Van Regenmortel, Ecole Superieure de Biotechnologie de Strasbourg (ESBS) Parc d’Innovation, Boulevard Se ´bastian Brandt, 67400 Illkirch, France. – Redaktion: Sachsenplatz 4–6, 1201 Wien, Austria – Hersteller: Satz und Umbruch: Thomson Press (India) Ltd., Chennai; Offsetdruck: Krips bv, Kaapweg 6, 7944 HV Meppel, The Netherlands – Verlagsort: Wien – Herstellungsort: Meppel – Printed in The Netherlands.
Archives of Virology – Springer Journals
Published: May 1, 2007
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera